Immunotherapy in Early-Stage Non-Small Cell Lung Cancer (NSCLC): Current Evidence and Perspectives

Immunotherapy in Early-Stage Non-Small Cell Lung Cancer (NSCLC): Current Evidence and Perspectives

Lung cancer is the leading cause of cancer deaths in the world. Surgery is the most potentially curative therapeutic option for patients with early-stage non-small cell lung cancer (NSCLC). The five-year survival for these patients remains poor and variable, depending on the stage of disease at diag...

Full description

Bibliographic Details
Main Authors: Chiara Lazzari, Calogera Claudia Spagnolo, Giuliana Ciappina, Martina Di Pietro, Andrea Squeri, Maria Ilenia Passalacqua, Silvia Marchesi, Vanesa Gregorc, Mariacarmela Santarpia
Format: Article
Language:English
Published: MDPI AG 2023-03-01
Series:Current Oncology
Subjects:
immunotherapy
immune checkpoint inhibitors
lung cancer
NSCLC
early stage
adjuvant
Online Access:https://www.mdpi.com/1718-7729/30/4/280

Internet

https://www.mdpi.com/1718-7729/30/4/280

Similar Items